Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pergoveris versus GONAL-f in poor ovarian responders undergoing ART
NL-OMON40576Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in female infertility and poor ovarian response (POR) comparing Pergoveris with GONAL-f (2 arms). Primary endpoint: Total number of retrieved oocytes per subject. Planned start Apr 2014; status: not yet recruiting.
02
Drugs
luteinizing hormonefollitropin alfa
03
Conditions
female infertilitypoor ovarian response (POR)
Beyond the preview
Go deeper on NL-OMON40576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40576.